Literature DB >> 32128637

Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications.

John Yfantopoulos1, Athanasios Chantzaras2.   

Abstract

OBJECTIVE: To evaluate the impact of multiple comorbidities/complications on health-related quality of life (HRQoL) and health utilities in insulin-treated type 2 diabetes (T2DM).
METHODS: In a non-interventional, epidemiological study, data were collected from medical records and via interviews for 938 subjects from various geographical areas of Greece. HRQoL and health utilities were explored with the EQ-5D-5L. Univariate associations were evaluated with the Mann-Whitney and Kruskal-Wallis tests for continuous and Chi-squared tests for nominal variables, and binary logistic regressions were employed to obtain marginal effects. Employing a split sample approach, various specifications of ordinary least squares regression models were evaluated in terms of goodness of fit, model specification, shrinkage and predictive and discriminative performance, to select the best model for mapping health utilities using the whole dataset.
RESULTS: Overall, the most important factors of impaired HRQoL and health utilities were higher age, female gender, obesity, poor glycemic control and increased duration of insulin treatment. History and increasing concurrence of all complications assessed were associated with exacerbated HRQoL problems, decreased health utilities and diminished health state, although it was not always statistically significant. The highest disutilities were associated with stroke (- 0.082), diabetic retinopathy (- 0.066), diabetic neuropathy (- 0.051) and severe hypoglycemia (- 0.050).
CONCLUSIONS: The deleterious impact of comorbidities on insulin-dependent T2DM subjects' HRQoL has been confirmed and clinicians should adapt the priorities of disease management accordingly. The derived health utility estimates may be valuable for conducting economic evaluations of interventions in the area of T2DM when data are not available.

Entities:  

Keywords:  EQ-5D; Greece; Health utilities; Health-related quality of life; Mapping; Type 2 diabetes

Mesh:

Substances:

Year:  2020        PMID: 32128637     DOI: 10.1007/s10198-020-01167-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  39 in total

1.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

Authors:  David R Whiting; Leonor Guariguata; Clara Weil; Jonathan Shaw
Journal:  Diabetes Res Clin Pract       Date:  2011-11-12       Impact factor: 5.602

2.  Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.

Authors:  Louise Longworth; Donna Rowen
Journal:  Value Health       Date:  2013 Jan-Feb       Impact factor: 5.725

3.  Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece.

Authors:  John N Yfantopoulos; Athanasios E Chantzaras
Journal:  Eur J Health Econ       Date:  2016-06-04

Review 4.  Quality of life and diabetes.

Authors:  R R Rubin; M Peyrot
Journal:  Diabetes Metab Res Rev       Date:  1999 May-Jun       Impact factor: 4.876

5.  A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM.

Authors:  R M Anderson; J T Fitzgerald; K Wisdom; W K Davis; R G Hiss
Journal:  Diabetes Care       Date:  1997-03       Impact factor: 19.112

6.  Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications.

Authors:  Nick Kontodimopoulos; Evelina Pappa; Zinovia Chadjiapostolou; Eleni Arvanitaki; Angelos A Papadopoulos; Dimitris Niakas
Journal:  Eur J Health Econ       Date:  2010-12-05

Review 7.  Review of utility values for economic modeling in type 2 diabetes.

Authors:  Amélie Beaudet; John Clegg; Per-Olof Thuresson; Adam Lloyd; Phil McEwan
Journal:  Value Health       Date:  2014-05-17       Impact factor: 5.725

8.  Comorbidity, health-related quality of life and self-care in type 2 diabetes: a cross-sectional study in an outpatient population.

Authors:  M P O'Shea; M Teeling; K Bennett
Journal:  Ir J Med Sci       Date:  2014-08-29       Impact factor: 1.568

9.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

10.  Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

Authors:  Paul Glasziou; Jan Alexander; Elaine Beller; Philip Clarke
Journal:  Health Qual Life Outcomes       Date:  2007-04-27       Impact factor: 3.186

View more
  3 in total

1.  Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China.

Authors:  Xiao-Mei Huang; Bo-Fan Yang; Wen-Lin Zheng; Qun Liu; Fan Xiao; Pei-Wen Ouyang; Mei-Jun Li; Xiu-Yun Li; Jing Meng; Tian-Tian Zhang; Yu-Hong Cui; Hong-Wei Pan
Journal:  BMC Health Serv Res       Date:  2022-02-25       Impact factor: 2.655

2.  Association between medication adherence and health-related quality of life of patients with diabetes.

Authors:  Athanasios Chantzaras; John Yfantopoulos
Journal:  Hormones (Athens)       Date:  2022-10-11       Impact factor: 3.419

3.  Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases.

Authors:  Shihchen Kuo; Chun-Ting Yang; Hsuan-Ying Chen; Huang-Tz Ou
Journal:  J Diabetes Investig       Date:  2021-03-02       Impact factor: 4.232

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.